These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 29243946

  • 1. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, Cairoli R, Montillo M.
    Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A.
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [Abstract] [Full Text] [Related]

  • 4. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN, O'Brien S.
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V.
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A, Kapsas G, Bezirgiannidou Z, Papamichos S, Kotsianidis Ι.
    Turk J Haematol; 2018 May 25; 35(2):147-149. PubMed ID: 29391330
    [No Abstract] [Full Text] [Related]

  • 9. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Barrientos J, Rai K.
    Leuk Lymphoma; 2013 Aug 25; 54(8):1817-20. PubMed ID: 23617325
    [Abstract] [Full Text] [Related]

  • 10. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y, Zhang LL, Champlin RE, Wang ML.
    Clin Pharmacol Ther; 2015 May 25; 97(5):455-68. PubMed ID: 25669675
    [Abstract] [Full Text] [Related]

  • 11. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Kaur V, Swami A.
    Ann Hematol; 2017 Jul 25; 96(7):1175-1184. PubMed ID: 28342031
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.
    JAMA Oncol; 2015 Apr 25; 1(1):80-7. PubMed ID: 26182309
    [Abstract] [Full Text] [Related]

  • 14. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A, Ravinet A, Bay JO, Tournilhac O, Guièze R, Lemal R.
    Bull Cancer; 2016 Feb 25; 103(2):127-37. PubMed ID: 26822906
    [Abstract] [Full Text] [Related]

  • 15. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G.
    Leukemia; 2017 Jul 25; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR.
    Leuk Lymphoma; 2014 Feb 25; 55(2):263-9. PubMed ID: 23656200
    [Abstract] [Full Text] [Related]

  • 18. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J, Jimeno A.
    Drugs Today (Barc); 2014 Apr 25; 50(4):291-300. PubMed ID: 24918646
    [Abstract] [Full Text] [Related]

  • 19. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.
    N Engl J Med; 2014 Jun 12; 370(24):2286-94. PubMed ID: 24869598
    [Abstract] [Full Text] [Related]

  • 20. Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Quintela A, Sujobert P, Callet-Bauchu E, Salles G, Baseggio L.
    Acta Haematol; 2017 Jun 12; 137(1):55-57. PubMed ID: 27960168
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.